Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q1 2026

BIO-TECHNE Q1 2026 Results: Net Income $28.3M, Down 25.9% YoY

Bio-Techne reported net sales of $299.7 million for the quarter ended September 30, 2026, a 4.6% increase over the prior year. However, net earnings decreased to $28.3 million from $38.2 million, primarily driven by higher selling, general, and administrative expenses and a shift in other income/expense.

Q1 2026 at a glance · $ million
MetricQ1 2026Q1 2025
Revenue299.7286.6
Gross profit196.6188.1
Profit before tax34.748.0
Net income28.338.2
EPS (diluted, $ a share)$0.18$0.24

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year-25.9%
Revenue, year on year+4.6%
Gross margin65.6%
Operating margin12.2%
Source

10-Q filed with the SEC, NASDAQ: TECH. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

BIO-TECHNE Corp: key numbers

Share price
$72.79Close, Nov 16
Market cap
$11.4B
Shares outstanding
157.06MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from BIO-TECHNE Corp

All →
6:03 AM ET 8-K
Dividend

BIO-TECHNE Dividend

Bio-Techne Corporation declared a quarterly cash dividend of $0.08 per share for the quarter ended September 30, 2026. The dividend is payable on November 23, 2026, to shareholders of record as of November 13, 2026, contingent upon the company's pending acquisition by Merck KGaA not closing before the record date.

5:09 PM ET 8-K
M&A Deal

BIO-TECHNE M&A Deal with Merck KGaA, Darmstadt, Germany

Bio-Techne shareholders voted to approve the company's acquisition by Merck KGaA, Darmstadt, Germany, at a special meeting held on September 23, 2026. The transaction has also cleared the HSR Act antitrust waiting period and is expected to close by late 2026 or early 2027. Bio-Techne will become a wholly-owned subsidiary of Merck KGaA upon completion of the merger.

Counterparty
Merck KGaA, Darmstadt, Germany
4:48 PM ET 8-K
M&A Deal

BIO-TECHNE M&A Deal with Merck KGaA, Darmstadt, Germany

Bio-Techne Corporation provided a status update on its pending merger with Merck KGaA, Darmstadt, Germany, specifically addressing shareholder litigation and demand letters alleging disclosure deficiencies in the proxy statement. To avoid potential delays to the merger and the scheduled September 23, 2026 shareholder vote, the company has voluntarily issued supplemental disclosures while maintaining that the legal claims are without merit.

Counterparty
Merck KGaA, Darmstadt, Germany

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.